Cardiometabolic diseases (CMD) are a direct consequence of modern living and contribute to the development of multisystem diseases such as cardiovascular diseases and diabetes mellitus (DM). CMD has reached epidemic proportions worldwide. A sodium pump (Na+/K+-ATPase) is found in most eukaryotic cells' membrane and controls many essential cellular functions directly or indirectly. This ion transporter and its isoforms are important in the pathogenesis of some pathological processes, including CMD. The structure and function of Na+/K+-ATPase, its expression and distribution in tissues, and its interactions with known ligands such as cardiotonic steroids and other suspected endogenous regulators are discussed in this review. In addition, we reviewed recent literature data related to the involvement of Na+/K+-ATPase activity dysfunction in CMD, focusing on the Na+/K+-ATPase as a potential therapeutic target in CMD.

Obradovic, M., Sudar-Milovanovic, E., Gluvic, Z., Banjac, K., Rizzo, M., Isenovic, E.R. (2023). The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases. FRONTIERS IN ENDOCRINOLOGY, 14 [10.3389/fendo.2023.1150171].

The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases

Rizzo, M;
2023-01-01

Abstract

Cardiometabolic diseases (CMD) are a direct consequence of modern living and contribute to the development of multisystem diseases such as cardiovascular diseases and diabetes mellitus (DM). CMD has reached epidemic proportions worldwide. A sodium pump (Na+/K+-ATPase) is found in most eukaryotic cells' membrane and controls many essential cellular functions directly or indirectly. This ion transporter and its isoforms are important in the pathogenesis of some pathological processes, including CMD. The structure and function of Na+/K+-ATPase, its expression and distribution in tissues, and its interactions with known ligands such as cardiotonic steroids and other suspected endogenous regulators are discussed in this review. In addition, we reviewed recent literature data related to the involvement of Na+/K+-ATPase activity dysfunction in CMD, focusing on the Na+/K+-ATPase as a potential therapeutic target in CMD.
2023
Obradovic, M., Sudar-Milovanovic, E., Gluvic, Z., Banjac, K., Rizzo, M., Isenovic, E.R. (2023). The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases. FRONTIERS IN ENDOCRINOLOGY, 14 [10.3389/fendo.2023.1150171].
File in questo prodotto:
File Dimensione Formato  
2023 Frontiers.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 1.8 MB
Formato Adobe PDF
1.8 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/620539
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact